BeOne Medicines Raises 2026 Revenue Guidance to $6.9 Billion-$7 Billion

PUBT · 1d ago
BeOne Medicines Raises 2026 Revenue Guidance to $6.9 Billion-$7 Billion
  • BeOne Medicines raised its 2026 revenue forecast to $6.9 billion-$7 billion from $6.6 billion-$6.8 billion.
  • GAAP operating income guidance increased to $1.2 billion-$1.3 billion from $1 billion-$1.1 billion.
  • Non-GAAP operating income is now projected at $1.9 billion-$2 billion, up from $1.7 billion-$1.8 billion.
  • The outlook includes an expected fourth-quarter reversal of certain valuation allowances, resulting in a material tax benefit.
  • Third-quarter revenue rose 34% to $1.89 billion, with BRUKINSA sales growing 34% to $1.39 billion.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeOne Medicines AG published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.